Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GUSB | P08236 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362411 | 0.85 | KMT2A (0.36) | LOXL2SRCPOLBKMT2AGUSB | |
| SCHEMBL13542691 | 0.85 | CYP1A2 (0.40) | LOXL2SRCPOLBKMT2AGUSB | |
| SCHEMBL16171672 | 0.84 | DDX3X (0.36) | LOXL2POLBKMT2A | |
| SCHEMBL21132611 | 0.80 | ADRB2 (0.41) | LOXL2 | |
| SCHEMBL18605543 | 0.80 | CYP4F2 (0.40) | SRCPOLBKMT2AGUSBFOLH1 | |
| SCHEMBL2628207 | 0.80 | CYP4F2 (0.40) | SRCPOLBKMT2AGUSBFOLH1 | |
| SCHEMBL27056928 | 0.79 | ALDH1A1 (0.40) | POLBKMT2AHDAC1FOLH1ITGAV | |
| SCHEMBL12573853 | 0.79 | ANPEP (0.43) | — | |
| SCHEMBL25098678 | 0.78 | POLB (0.37) | POLBKMT2AHDAC1ITGAVITGB5 | |
| SCHEMBL19296374 | 0.77 | CYP1A2 (0.39) | HDAC1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295092-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20180194729-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-07-12 | — | — | US | disclosed |
| US-10016519-B2 | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | DEUTSCHES KREBSFORSCHUNGSZENTRIUM (DE) | 2018-07-10 | — | — | US | disclosed |
| US-20170246327-A1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Ruprecht-Karls-Universität Heidelberg (DE) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194729-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | KLK3, FOLH1, MPI | LOXL2 4058/4885SRC 3565/4885POLB 3793/4885 |
| US-10016519-B2 | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | KLK3, FOLH1, PSMA6 | LOXL2 4371/4885SRC 3602/4885POLB 3902/4885 |
| US-20230295092-A1 | 18F - TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND THEIR USE AS IMAGING AGENTS FOR PROSTATE CANCER | KLK3, FOLH1, MPI | LOXL2 4058/4885SRC 3565/4885POLB 3793/4885 |
| US-20170246327-A1 | 18F-TAGGED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, FOLH1, PSMA6 | LOXL2 4371/4885SRC 3602/4885POLB 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.